抗生素
小分子
药品
计算生物学
抗菌剂
药物发现
药物开发
免疫系统
化学
生物
医学
药理学
生物信息学
微生物学
免疫学
生物化学
作者
Peter J. Cossar,Peter J. Lewis,Adam McCluskey
摘要
Abstract There are 27 small molecule protein‐protein interaction (PPI) modulators in Phase I, II, and III clinical trials targeting cancer, viruses, autoimmune disorders, and as immune suppression agents. Targeting PPIs as an antibiotic drug discovery strategy remains in relative infancy by comparison. However, a number of molecules are in development which target PPI within the replisome, divisome, transcriptome, and translatome are showing significant promise at the medicinal chemistry stage of drug development. Hence, the success of future PPI agents as antibiotics will build upon the techniques and design strategies of these molecules.
科研通智能强力驱动
Strongly Powered by AbleSci AI